Quantitative Concept – Page 3

Ayrmid misses deadline for detailed offer to top private equity bid for bluebird

2 weeks ago talkbio0Tagged Ayrmid, Capital, deadline, Failed, Family Turdidae (organism), gene therapy, Private Equity, proposal - intent, United States Food and Drug Administration

Ayrmid, Family Turdidae (organism), gene therapy, Failed, Capital, proposal – intent, United States Food and Drug Administration, private equity, deadline

Trump pledges his support for a change to the IRA long sought by drugmakers

2 weeks ago talkbio0Tagged Biological Factors, Contraceptives, Oral, drug price, drugmakers, Industry, IRA, Mediation, Medicare, Prices

IRA, Medicare, Contraceptives, Oral, Mediation, Industry, drug price, Biological Factors, Prices, drugmakers, Medicare

J&J brushes off tariff headwinds with raised forecast, oncology surge

2 weeks ago talkbio0Tagged Caplyta, Growth, Increased, Intra-Cellular Therapies, J&J, Johnson and Johnson, Neoplasms, Projections and Predictions, Raised, Sales - occupational activity, United States

J&J, United States, Sales – occupational activity, Neoplasms, Johnson and Johnson, Caplyta, Intra-Cellular Therapies, Raised, Increased, Growth, Projections and Predictions

Sanofi backs $90M financing for I&I biologic developer

2 weeks ago talkbio0Tagged financing characteristics, I&I, sanofi, Series

sanofi, Series, financing characteristics, II

Leqembi wins EU authorization for some Alzheimer’s patients, giving Biogen, Eisai a boost over Lilly

2 weeks ago talkbio0Tagged Alzheimer, Apolipoprotein E4, ARIA, authorization, Biogen, Eisai, Eli Lilly, EU, High, Kisunla, Leqembi, Restricted

Leqembi, EU, Eisai, Eli Lilly, ARIA, Biogen, authorization, Alzheimer, Kisunla, Restricted, Apolipoprotein E4, High

Merck inks $493M biobucks deal to use Cyprumed’s tech to create oral peptides

2 weeks ago talkbio0Tagged biobucks, Cyprumed, Merck, Peptides

Cyprumed, Merck, biobucks, Peptides

Mural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternatives

2 weeks ago talkbio0Tagged 90%, Interleukin-2, Mural, Mural Oncology, Nemvaleukin Alfa, strategic alternatives

Interleukin-2, Mural Oncology, Mural, strategic alternatives, Nemvaleukin Alfa, 90%

Third Harmonic Bio to Liquidate, Selling Key Urticaria Drug Asset THB335

2 weeks ago talkbio0Tagged biopharma exit strategy, Chronic Spontaneous Urticaria, clinical-stage, CSU, drug sales, Inhibitor, KIT, Kit device, shareholder, THB335, Third Harmonic Bio liquidation, value maximization

Third Harmonic Bio liquidation , THB335 drug sale , chronic spontaneous urticaria (CSU) , KIT inhibitor , biopharma exit strategy , clinical-stage biotech , shareholder value maximization

PRISM BioLab and Elix Collaborate to Revolutionize AI-Driven Drug Discovery with Peptide Mimetics

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Drug Discovery, Efficiency, Elix, mimetics, PepMetics, Peptides, pharmaceutical innovation, PRISM BioLab, Protein-Protein Interaction, small molecule inhibitors

PRISM BioLab , Elix , AI drug discovery , Peptide mimetics , Protein-protein interactions , PepMetics® , Small molecule inhibitors , Drug discovery efficiency , Pharmaceutical innovation

FDA Union Prepares for Negotiations as HHS Job Cuts Reshape Workforce

2 weeks ago talkbio0Tagged Advocacy, CHARGE Syndrome, employee layoffs, federal, Force, layoffs, Mediation, public health medicine (field), reduction in force, restructuring, Union, United States Food and Drug Administration

FDA layoffs, HHS restructuring, Union negotiations, Reduction in Force (RIF), Robert F. Kennedy Jr., FDA workforce reduction, HHS employee layoffs, Federal health agencies, Public health impact, Union advocacy